Integral Derivatives Lifted Bsx (Put) (BSX) Holding By $1.00 Million; Mangrove Partners Has Boosted Its Ani Pharmaceuticals (ANIP) Position

October 23, 2017 - By Vivian Currie

Integral Derivatives Llc increased Bsx (Put) (BSX) stake by 108.16% reported in 2017Q2 SEC filing. Integral Derivatives Llc acquired 37,100 shares as Bsx (Put) (BSX)’s stock rose 4.02%. The Integral Derivatives Llc holds 71,400 shares with $1.98 million value, up from 34,300 last quarter. Bsx (Put) now has $40.63B valuation. The stock decreased 0.27% or $0.08 during the last trading session, reaching $29.61. About 4.49 million shares traded or 2.98% up from the average. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since October 23, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Mangrove Partners increased Ani Pharmaceuticals Inc (ANIP) stake by 379.43% reported in 2017Q2 SEC filing. Mangrove Partners acquired 221,491 shares as Ani Pharmaceuticals Inc (ANIP)’s stock declined 26.94%. The Mangrove Partners holds 279,866 shares with $13.10 million value, up from 58,375 last quarter. Ani Pharmaceuticals Inc now has $684.80 million valuation. The stock decreased 0.42% or $0.25 during the last trading session, reaching $58.84. About 116,109 shares traded or 5.52% up from the average. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has declined 0.02% since October 23, 2016 and is downtrending. It has underperformed by 16.72% the S&P500.




Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. ANI Pharma had 17 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Wednesday, August 9 with “Buy”. The rating was maintained by Oppenheimer with “Outperform” on Friday, August 5. As per Tuesday, May 24, the company rating was downgraded by Standpoint Research. The firm earned “Buy” rating on Wednesday, September 2 by TheStreet. The company was upgraded on Tuesday, July 19 by Oppenheimer. Oppenheimer maintained the stock with “Outperform” rating in Friday, July 31 report. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Neutral” rating given on Tuesday, August 4 by TH Capital. The firm has “Buy” rating by Standpoint Research given on Friday, November 13. The rating was initiated by Raymond James with “Strong Buy” on Thursday, June 23. The firm earned “Buy” rating on Monday, October 16 by Canaccord Genuity.

Investors sentiment decreased to 1.06 in 2017 Q2. Its down 0.34, from 1.4 in 2017Q1. It dived, as 20 investors sold ANIP shares while 42 reduced holdings. 17 funds opened positions while 49 raised stakes. 6.39 million shares or 4.42% more from 6.12 million shares in 2017Q1 were reported. Ranger Invest Lp reported 0.08% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Winslow Evans & Crocker accumulated 8 shares. Ameriprise Financial Inc stated it has 54,205 shares. Mark Sheptoff Fincl Planning Limited Company has invested 0.18% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Raymond James Associate holds 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 5,014 shares. State Of Wisconsin Board reported 6,000 shares. Wolverine Asset Management Ltd Liability invested 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Architects has 0% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 75 shares. 3,782 are held by Barclays Pcl. Ativo Cap Mngmt Llc invested 0.33% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Royal Bancorporation Of Canada holds 0% or 88 shares. 7,541 were accumulated by State Of Tennessee Treasury Department. Pnc Services Grp owns 71,160 shares. Envestnet Asset Mngmt Inc has 3,337 shares for 0% of their portfolio. Swiss Natl Bank holds 0% or 14,800 shares.

Investors sentiment increased to 1.03 in 2017 Q2. Its up 0.14, from 0.89 in 2017Q1. It improved, as 41 investors sold BSX shares while 173 reduced holdings. 56 funds opened positions while 165 raised stakes. 1.22 billion shares or 0.64% less from 1.23 billion shares in 2017Q1 were reported. Atalanta Sosnoff Cap Limited Company reported 1.21% in Boston Scientific Corporation (NYSE:BSX). Proshare Advsr Llc accumulated 132,776 shares or 0.04% of the stock. Moreover, Seaward Ltd Partnership has 1.46% invested in Boston Scientific Corporation (NYSE:BSX). Swiss Bancorporation owns 0.18% invested in Boston Scientific Corporation (NYSE:BSX) for 5.58M shares. Diligent Invsts Limited Liability stated it has 0.22% in Boston Scientific Corporation (NYSE:BSX). Jnba Financial accumulated 7,298 shares. Meiji Yasuda Asset Management Co Limited accumulated 52,211 shares. Advisory Service Limited Liability accumulated 1,002 shares or 0% of the stock. Tru Of Vermont holds 0.01% or 4,221 shares. Clough Ptnrs LP holds 257,400 shares. Norinchukin National Bank The invested 0.05% of its portfolio in Boston Scientific Corporation (NYSE:BSX). United Kingdom-based Legal General Group Public Ltd has invested 0.15% in Boston Scientific Corporation (NYSE:BSX). Pdts Prns Lc accumulated 909,500 shares. Commonwealth Commercial Bank Of Aus reported 73,572 shares stake. Rainier Inv Mngmt Ltd Company reported 45,660 shares.

Since May 1, 2017, it had 0 buys, and 7 insider sales for $2.58 million activity. Ballinger Kevin J. sold $754,454 worth of stock. Another trade for 15,500 shares valued at $408,778 was made by Phalen Michael P. on Monday, May 1. The insider Pratt Timothy A. sold 10,000 shares worth $263,728. Pierce David A sold $379,736 worth of stock.

Integral Derivatives Llc decreased Kmx (Call) (NYSE:KMX) stake by 5,100 shares to 19,900 valued at $1.26M in 2017Q2. It also reduced Pg (Put) (NYSE:PG) stake by 54,200 shares and now owns 6,600 shares. Aal (Call) (NASDAQ:AAL) was reduced too.

Among 27 analysts covering Boston Scientific Corporation (NYSE:BSX), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Boston Scientific Corporation had 63 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, May 1 by Oppenheimer. Needham maintained the shares of BSX in report on Friday, July 29 with “Buy” rating. BMO Capital Markets maintained it with “Buy” rating and $3000 target in Thursday, July 27 report. The firm has “Buy” rating given on Thursday, July 27 by Cowen & Co. As per Wednesday, June 28, the company rating was maintained by Oppenheimer. The rating was maintained by JP Morgan on Friday, July 29 with “Overweight”. BMO Capital Markets maintained the shares of BSX in report on Wednesday, October 11 with “Buy” rating. The rating was maintained by Citigroup on Thursday, October 6 with “Buy”. The firm earned “Corporate” rating on Thursday, October 29 by FinnCap. On Thursday, August 13 the stock rating was downgraded by TheStreet to “Hold”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.